TT 301

Drug Profile

TT 301

Alternative Names: TT301

Latest Information Update: 14 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Northwestern University
  • Developer Transition Therapeutics
  • Class Antidementias; Antirheumatics; Small molecules
  • Mechanism of Action Cytokine inhibitors; Glial cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I CNS disorders
  • Preclinical Alzheimer's disease; Rheumatoid arthritis

Most Recent Events

  • 31 Aug 2016 Transition Therapeutics has been acquired by OPKO Health
  • 06 Jul 2011 Transition Therapeutics completes enrolment in its phase I trial in Healthy volunteers in Canada
  • 30 Jun 2011 Transition Therapeutics completes a phase I trial in Healthy volunteers in USA (NCT01357421)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top